AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for prostate tissue ablation. The clearance for the NanoKnife System for prostate ...

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

Function-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate Tumors AngioDynamics, Inc. (NASDAQ: ANGO), ...

TIME names NanoKnife one of 2025’s Best Inventions — already treating prostate cancer in Toronto with precise, function-preserving results. TIME's recognition of NanoKnife (IRE) reinforces what we’ve ...

At the recent American Urological Association (AUA) annual meeting, focal therapies for localized prostate cancer took center stage, moving from a niche option to a recognized alternative to surgery ...

PSA testing and digital rectal exams are crucial for early detection of prostate cancer, enabling timely intervention and improved outcomes. Treatment options include active surveillance, surgery, ...

Investigator initiated trial seeks to validate safety, efficacy of the NanoKnife System in treating targeted tumors while reducing or delaying need for radical intervention Approximately 40% of all ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options ...